aspirin has been researched along with hydrochlorothiazide in 67 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (13.43) | 18.7374 |
| 1990's | 3 (4.48) | 18.2507 |
| 2000's | 19 (28.36) | 29.6817 |
| 2010's | 25 (37.31) | 24.3611 |
| 2020's | 11 (16.42) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Huvenne, JP; Smahi, Z; Traisnel, M | 1 |
| Cooper, JA; Matthay, RA | 1 |
| Blaser, KU; Lämmle, B | 1 |
| Kanig, JL; Rhodes, CT; Rudnic, EM | 1 |
| Garcia, HA; Hofmann, LM; Krupnick, MI | 1 |
| Nimmo, J; Prescott, LF | 1 |
| Favre, L; Jörg, J; Vallotton, MB; Vierhapper, H; Waldhäusl, W | 1 |
| Monn, E | 1 |
| Kolloch, RE; Rahn, KH | 1 |
| Cornell, ES; Heckbert, SR; Psaty, BM; Smith, NL; Tracy, RP | 1 |
| Caldwell, GG; Evangelisto, M; Jones, WW; Juzwin, SS; Masucci, JJ; Sasso, PP | 1 |
| MASON, RM | 1 |
| CHRISTENSSON, B; GUSTAFSON, A; WESTLING, H | 1 |
| George, A; Shakib, S | 1 |
| Cooper, JA; Eggert, M; Lock, BJ | 1 |
| Bajraktari, G; Beqiri, A; Berisha, I; Elezi, S; Kastrati, S; Manaj, R; Thaqi, S | 1 |
| Dan, N; Kahn, JB; Metzger, K; Siegel, SJ; Werner, K; Winey, KI | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Forslund, L | 1 |
| Afzal, R; Pais, P; Pogue, J; Sigamani, A; Xavier, D; Yusuf, S | 1 |
| Afzal, R; Eikelboom, J; Gupta, R; Mohan, V; Pais, P; Sigamani, A; Teo, K; Thomas, N; Xavier, D; Yusuf, S | 1 |
| Kerchner, K; Sangüeza, OP; Walsh, SN | 1 |
| Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T | 1 |
| Aslani, A; Cheng, KK; Gharravi, M; Khoshnia, M; Larijani, B; Malekzadeh, F; Malekzadeh, R; Marshall, T; Nateghi, A; Pourshams, A; Rastegarpanah, M; Salahi, R; Semnani, S; Thomas, GN | 1 |
| Day, RO; Graham, GG; Ng, DY; Stocker, SL; Williams, KM | 1 |
| Dissanayake, WP; Furberg, CD; Gunaratne, PS; Jayasingne, IK; Mendis, S; Soliman, EZ; Somasundaram, NP | 1 |
| Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO | 1 |
| Afzal, R; Gao, P; Pais, P; Sigamani, A; Teo, KK; Xavier, D; Yusuf, S | 1 |
| Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R | 1 |
| Billot, L; Bompoint, S; Bots, ML; Cidambi, R; Field, J; Grobbee, DE; Patel, A; Poulter, N; Prabhakaran, D; Reddy, KS; Rodgers, A; Stanton, A; Thom, S | 1 |
| Billot, L; Bompoint, S; Brown, A; Burch, C; Burke, H; Cass, A; Hayman, N; Hillis, GS; Jan, S; Molanus, B; Neal, B; Patel, A; Peiris, D; Rafter, N; Reid, CM; Rodgers, A; Shiel, L; Togni, S; Tonkin, A; Usherwood, T; Webster, R | 1 |
| Cheng, KK; Etemadi, A; Hemming, K; Jaafari, E; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marjani, H; Marshall, T; Merat, S; Mohammadifard, N; Naemi, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Sadeghi, M; Sarrafzadegan, N; Thomas, GN | 1 |
| Hemming, K; Jafari, E; Khoshnia, M; Malekzadeh, R; Marshall, T; Merat, S; Nateghi, A; Poustchi, H; Radmard, AR; Shiravi Khuzani, A | 1 |
| Alexander, MR; Burley, JC; Khaled, SA; Roberts, CJ; Yang, J | 1 |
| Luteijn, JM; Morris, JK; Oppenheimer, P; Taylor, D; Wald, NJ | 1 |
| Bots, ML; Grobbee, DE; Lafeber, M; Patel, A; Prabhakaran, D; Rodgers, A; Spiering, W; Stanton, A; Thom, S; Visseren, FL; Webster, R | 1 |
| Cheruvu, HS; Devalapalli, MMR; Sampathi, S; Shivakumar, S; Veeravalli, VB; Yertha, T | 1 |
| Apola, A; Hubicka, U; Kwiecień, A; Maślanka, A; Opoka, W; Stolarczyk, M | 1 |
| Boffetta, P; Brennan, P; Cheng, KK; Etemadi, A; Fazel, A; Gharavi, A; Hemming, K; Kamangar, F; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marshall, T; Merat, S; Mohammadifard, N; Naemi-Tabiei, M; Nalini, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Roshandel, G; Sadeghi, M; Sarrafzadegan, N; Thomas, N | 1 |
| Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS; Serag, A | 1 |
| Abtahi, F; Anushiravani, A; Fattahi, MR; Gandomkar, A; Malekzadeh, F; Malekzadeh, R; Malekzadeh, Z; Merat, S; Moghadami, M; Mohammadkarimi, V; Moini, M; Mortazavi, R; Poustchi, H; Sadeghi Boogar, S; Sepanlou, SG | 1 |
| Bosch, J; Christou, C; Dagenais, G; Dans, A; Gamra, H; Gao, P; Girish, P; Joseph, P; López-Jaramillo, P; McCready, T; Pais, P; Rocha, C; Santoso, A; Talukder, S; Teo, K; Tyrwhitt, J; Xavier, D; Xavier, F; Yeates, K; Yusoff, K; Yusuf, S | 1 |
| Fiorina, P; Gallieni, M; Paik, JM | 1 |
| Alam, A; Carey, SA; Hall, SA | 1 |
| Bangalore, S; Brguljan, J; Messerli, FH | 1 |
| Law, M; Wald, D; Wald, N | 1 |
| Cainzos-Achirica, M | 1 |
| Aurit, SJ; Bashir, K; Burns, T; Hilleman, DE; Pirruccello, SJ | 1 |
| Bosch, JJ; Dans, A; Gao, P; Joseph, P; Lopez Jaramillo, P; O'Donnell, MJ; Pais, P; Xavier, D; Yusuf, S | 1 |
4 review(s) available for aspirin and hydrochlorothiazide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug-induced pulmonary disease.
Topics: Anti-Arrhythmia Agents; Anticonvulsants; Antineoplastic Agents; Aspirin; Gold; Humans; Hydrochlorothiazide; Narcotics; Nitrofurantoin; Penicillamine; Pulmonary Edema; Pulmonary Fibrosis; Respiratory Hypersensitivity; Ritodrine; Sulfasalazine; Terbutaline | 1987 |
Infiltrative lung disease due to noncytotoxic agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Humans; Hydrochlorothiazide; Iatrogenic Disease; Kidney Diseases; Lung Diseases; Lung Diseases, Interstitial; Methotrexate; Narcotics; Organogold Compounds; Syndrome | 2004 |
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Simvastatin; Stroke | 2012 |
18 trial(s) available for aspirin and hydrochlorothiazide
| Article | Year |
|---|---|
[The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Diastole; Diuretics; Felodipine; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Sodium Chloride Symporter Inhibitors; Time Factors | 1998 |
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atenolol; Capsules; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Drug Costs; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Research Design; Secondary Prevention; Simvastatin; Treatment Outcome | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Risk Reduction Behavior; Simvastatin; Treatment Outcome | 2009 |
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Aspirin; Atenolol; Biological Availability; Capsules; Cardiovascular Diseases; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Drug Interactions; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Simvastatin; Tandem Mass Spectrometry; Young Adult | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disease; Double-Blind Method; Drug Combinations; Enalapril; Female; Heptanoic Acids; Humans; Hydrochlorothiazide; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Tablets | 2010 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Chi-Square Distribution; Cholesterol; Diuretics; Drug Combinations; Feasibility Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Primary Prevention; Risk Assessment; Risk Factors; Simvastatin; Sri Lanka; Surveys and Questionnaires; Time Factors; Treatment Outcome; World Health Organization | 2011 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; Capsules; Cardiovascular Diseases; Cholesterol, LDL; Creatinine; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; India; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Potassium; Ramipril; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2012 |
The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Topics: Administration, Oral; Antihypertensive Agents; Aspirin; Biomarkers; Blood Platelets; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Cross-Over Studies; Drug Chronotherapy; Drug Combinations; Dyslipidemias; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lisinopril; Netherlands; Platelet Aggregation Inhibitors; Primary Prevention; Prospective Studies; Research Design; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2014 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Female; Humans; Hydrochlorothiazide; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin; Treatment Outcome | 2013 |
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Australia; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cholesterol; Drug Combinations; Drugs, Generic; Female; General Practice; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lisinopril; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Primary Prevention; Prospective Studies; Risk Factors; Simvastatin; Sodium Chloride Symporter Inhibitors; Tablets; Time Factors; Treatment Outcome | 2015 |
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Protocols; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Polypharmacy; Primary Prevention; Research Design; Secondary Prevention; Sodium Chloride Symporter Inhibitors; Time Factors; Treatment Outcome; Valsartan | 2015 |
PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Atorvastatin; Cardiovascular Diseases; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Platelet Aggregation Inhibitors; Urban Population; Valsartan | 2015 |
Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Drug Substitution; Europe; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2017 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Valsartan | 2019 |
Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial.
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Female; Humans; Hydrochlorothiazide; Iran; Male; Middle Aged; Pragmatic Clinical Trials as Topic | 2020 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Incidence; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin | 2021 |
Comparative antiplatelet effects of chlorthalidone and hydrochlorothiazide.
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Chlorthalidone; Diuretics; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; Prospective Studies | 2022 |
Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cognition; Drug Combinations; Female; Humans; Hydrochlorothiazide | 2023 |
45 other study(ies) available for aspirin and hydrochlorothiazide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[HPLC used in the validation of simple methods for research of degradation products in essential drug tablets].
Topics: Aspirin; Chromatography, High Pressure Liquid; Colorimetry; Developing Countries; Drug and Narcotic Control; Humans; Hydrochlorothiazide; Quality Control; Tablets | 1992 |
[Acute hyperkalemia and non-oliguric kidney failure during treatment with indomethacin, allopurinol, nifedipine, hydrochlorothiazide/amiloride, trimethoprim/sulfamethoxazole and acetylsalicylic acid].
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Allopurinol; Amiloride; Aspirin; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyperkalemia; Indomethacin; Male; Nifedipine; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1988 |
Effect of molecular structure variation on the disintegrant action of sodium starch glycolate.
Topics: Aspirin; Chemical Phenomena; Chemistry, Physical; Drug Compounding; Excipients; Glycolates; Hardness Tests; Hydrochlorothiazide; Solubility; Tablets; Temperature; Water | 1985 |
Interactions of spironolactone and hydrochlorothiazide with aspirin in the rat and dog.
Topics: Aldosterone; Animals; Aspirin; Corticosterone; Diuresis; Diuretics; Dogs; Drug Interactions; Female; Hydrochlorothiazide; Kidney; Male; Mineralocorticoids; Natriuresis; Potassium; Rats; Rats, Inbred Strains; Spironolactone | 1972 |
Generic inequivalence--clinical observations.
Topics: Absorption; Acetaminophen; Administration, Oral; Adult; Aspirin; Biopharmaceutics; Capsules; Chloramphenicol; Delayed-Action Preparations; Drug Compounding; Female; Humans; Hydrochlorothiazide; Phenacetin; Prednisone; Tablets; Tablets, Enteric-Coated; Tetracycline; Therapeutic Equivalency; Time Factors; Tolbutamide; Triamterene | 1971 |
Comparative therapeutic benefit of indomethacin, hydrochlorothiazide, and acetyl-salicylic acid in a patient with nephrogenic diabetes insipidus.
Topics: Adolescent; Aspirin; Diabetes Insipidus; Diabetic Nephropathies; Dinoprost; Dinoprostone; Diuresis; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Indomethacin; Male; Osmolar Concentration; Prostaglandins E; Prostaglandins F; Sodium; Thirst; Vasopressins | 1984 |
Prostaglandin synthetase inhibitors in the treatment of nephrogenic diabetes insipidus.
Topics: Aspirin; Body Water; Child; Cyclooxygenase Inhibitors; Diabetes Insipidus; Humans; Hydrochlorothiazide; Hypernatremia; Indomethacin; Infant; Kidney; Male; Polyuria | 1981 |
The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly.
Topics: Aged; Aspirin; Cardiovascular Agents; Digoxin; Humans; Hydrochlorothiazide; Patient Compliance; Propranolol; Reproducibility of Results | 1999 |
The use of on-line and off-line chromatographic extraction techniques coupled with mass spectrometry for support of in vivo and in vitro assays in drug discovery.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Caco-2 Cells; Chromatography, Liquid; Cimetidine; Drug Evaluation, Preclinical; Gas Chromatography-Mass Spectrometry; Histamine H1 Antagonists; Humans; Hydrochlorothiazide; Pharmaceutical Preparations; Phosphodiesterase Inhibitors; Promethazine; Theophylline | 2001 |
INFLAMMATORY POLYARTHRITIC DISEASE. IV. GOUT.
Topics: Arthritis; Aspirin; Chlorothiazide; Colchicine; Gout; Hydrochlorothiazide; Mecamylamine; Pempidine; Phenylbutazone; Probenecid; Pyrazoles; Salicylates | 1963 |
THE EFFECT OF SALURETICS ON PULSE RATE, BLOOD PRESSURE AND ELECTROCARDIOGRAM DURING EXERCISE IN NORMAL SUBJECTS.
Topics: Aspirin; Biomedical Research; Blood; Blood Pressure; Blood Pressure Determination; Chlorides; Chlorthalidone; Diuretics; Edema; Electrocardiography; Exercise Test; Extracellular Space; Heart Rate; Hematocrit; Hemoglobins; Hydrochlorothiazide; Hypertension; Hypokalemia; Pharmacology; Physical Exertion; Potassium; Pulse; Sodium; Toxicology; Water-Electrolyte Balance | 1964 |
Introduction to monitoring. What is what you prescribed actually doing?
Topics: Acetaminophen; Aged; Aspirin; Australia; Celecoxib; Drug Interactions; Drug Therapy, Combination; Family Practice; Female; Fosinopril; Humans; Hydrochlorothiazide; Hypertension; Monitoring, Physiologic; Osteoarthritis, Knee; Pyrazoles; Risk Assessment; Sensitivity and Specificity; Stroke; Sulfonamides | 2003 |
Acute myocardial infarction in a patient with severe unrecognized mitral stenosis.
Topics: Analgesics; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Diuretics; Echocardiography, Transesophageal; Electrocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydrochlorothiazide; Metoprolol; Middle Aged; Mitral Valve Stenosis; Myocardial Infarction; Nadroparin; Simvastatin; Time Factors; Treatment Outcome | 2006 |
Effect of drug type on the degradation rate of PLGA matrices.
Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Aspirin; Biocompatible Materials; Corticosterone; Delayed-Action Preparations; Diffusion; Drug Carriers; Haloperidol; Hydrochlorothiazide; Hydrolysis; Ibuprofen; Kinetics; Lactic Acid; Models, Chemical; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Solubility; Thiothixene; Time Factors | 2006 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Reflections on the regulation of the Polypill.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Approval; Drug Combinations; Europe; Folic Acid; Government Regulation; Health Policy; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Treatment Outcome | 2009 |
Challenge. What is your diagnosis? Answer. Primary nodal diffuse large B-cell lymphoma with secondary cutaneous involvement.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Artery Disease; Diuretics; Exanthema; Humans; Hydrochlorothiazide; Lisinopril; Lymphoma, Large B-Cell, Diffuse; Male; Platelet Aggregation Inhibitors; Skin Neoplasms; Sotalol; Stents; Ticlopidine | 2009 |
Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.
Topics: Adolescent; Adult; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chromatography, High Pressure Liquid; Diuretics; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hydrochlorothiazide; Kidney; Kidney Function Tests; Male; Middle Aged; Oxypurinol; Uric Acid; Young Adult | 2011 |
3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles.
Topics: Aspirin; Atenolol; Delayed-Action Preparations; Drug Combinations; Drug Liberation; Excipients; Hydrochlorothiazide; Powder Diffraction; Pravastatin; Printing, Three-Dimensional; Ramipril; Solubility; Spectroscopy, Fourier Transform Infrared; Tablets; X-Ray Diffraction | 2015 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort Studies; Cost-Benefit Analysis; Humans; Hydrochlorothiazide; Losartan; Markov Chains; Middle Aged; Myocardial Infarction; Polypharmacy; Primary Prevention; Quality-Adjusted Life Years; Simvastatin; Stroke; United Kingdom | 2016 |
Hansen solubility parameters for assay method optimization of simvastatin, ramipril, atenolol, hydrochlorothiazide and aspirin in human plasma using liquid chromatography with tandem mass spectrometry.
Topics: Aspirin; Atenolol; Chromatography, Liquid; Humans; Hydrochlorothiazide; Ramipril; Reproducibility of Results; Simvastatin; Solubility; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2017 |
Simultaneous Determination of Acetylsalicylic Acid, Hydrochlorothiazide, Enalapril, and Atorvastatin in a Polypill-Based Quaternary Mixture by TLC.
Topics: Aspirin; Atorvastatin; Cardiotonic Agents; Chromatography, Thin Layer; Densitometry; Drug Compounding; Enalapril; Hydrochlorothiazide; Limit of Detection; Reproducibility of Results | 2018 |
Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.
Topics: Algorithms; Aspirin; Atenolol; Capsules; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Least-Squares Analysis; Ramipril; Simvastatin; Spectrophotometry, Ultraviolet | 2020 |
Polypill in Persons without Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Hydrochlorothiazide | 2021 |
Polypill in Persons without Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Hydrochlorothiazide | 2021 |
Polypill in Persons without Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Hydrochlorothiazide | 2021 |
Polypill in Persons without Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Hydrochlorothiazide | 2021 |
Polypill in Persons without Cardiovascular Disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Humans; Hydrochlorothiazide | 2021 |